Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Active Bathing to Eliminate Infection (ABATE Infection) Trial
Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial)
Status: Enrolling
Updated:  1/16/2018
St. Petersburg General Hospital
mi
from
Saint Petersburg, FL
Active Bathing to Eliminate Infection (ABATE Infection) Trial
Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial)
Status: Enrolling
Updated: 1/16/2018
St. Petersburg General Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
University of California at San Francisco
mi
from
San Francisco, CA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Cancer Center of Florida
mi
from
Orlando, FL
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Cancer Center of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Georgia Cancer Specialists
mi
from
Atlanta, GA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC
mi
from
Detroit, MI
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Henry Ford Health System
mi
from
Detroit, MI
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Washington University School of Medicine - St Louis, MO
mi
from
Saint Louis, MO
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Washington University School of Medicine - St Louis, MO
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Joan and Sanford I. Weill Medical College, Cornell University
mi
from
New York, NY
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Joan and Sanford I. Weill Medical College, Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Cleveland Clinic Foundation, Univ. of Ohio
mi
from
Cleveland, OH
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Cleveland Clinic Foundation, Univ. of Ohio
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Hematology Oncology Associates of South Texas
mi
from
San Antonio, TX
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Hematology Oncology Associates of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated:  1/18/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated: 1/18/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated:  1/18/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated: 1/18/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated:  1/18/2018
Massachusetts General Hospital
mi
from
Boston, MA
Bortezomib Plus Rituximab for EBV+ PTLD
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
Status: Enrolling
Updated: 1/18/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 250 mg Clarithromycin Tablets Under Fasting Conditions
Status: Enrolling
Updated:  1/19/2018
MDS Pharma Services
mi
from
Phoenix, AZ
Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 250 mg Clarithromycin Tablets Under Fasting Conditions
Status: Enrolling
Updated: 1/19/2018
MDS Pharma Services
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
MDS Pharma Services
mi
from
Phoenix, AZ
Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
MDS Pharma Services
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
Novum Pharmaceutical Research Services
mi
from
Houston, TX
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
Novum Pharmaceutical Research Services
mi
from
Houston, TX
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
Dinuba, CA
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
Dinuba, CA
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
Miami, FL
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
Plantation, FL
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
Nashville, TN
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated:  1/22/2018
Clinical Research Facility
mi
from
Richland, WA
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice
Status: Enrolling
Updated: 1/22/2018
Clinical Research Facility
mi
from
Richland, WA
Click here to add this to my saved trials
Autologous Fecal Therapy
Restoration of the Fecal Microbiome After Antimicrobial Exposure With Autologous Fecal Flora Restoration Therapy
Status: Enrolling
Updated:  1/23/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Autologous Fecal Therapy
Restoration of the Fecal Microbiome After Antimicrobial Exposure With Autologous Fecal Flora Restoration Therapy
Status: Enrolling
Updated: 1/23/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents
Status: Enrolling
Updated:  1/23/2018
Columbia University Medical Center
mi
from
New York, NY
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents
Status: Enrolling
Updated: 1/23/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
First Allergy and Clinical Research Center
mi
from
Centennial, CO
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
First Allergy and Clinical Research Center
mi
from
Centennial, CO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Pediatrics Allergy/Immunology Association, PA
mi
from
Dallas, TX
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Pediatrics Allergy/Immunology Association, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
Stanford Cancer Center
mi
from
Stanford, CA
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  1/24/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 1/24/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Challenge Model for Assessment of Human TB Immunity
Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity
Status: Enrolling
Updated:  1/25/2018
Emory Vaccine Center - The Hope Clinic
mi
from
Decatur, GA
Challenge Model for Assessment of Human TB Immunity
Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity
Status: Enrolling
Updated: 1/25/2018
Emory Vaccine Center - The Hope Clinic
mi
from
Decatur, GA
Click here to add this to my saved trials
Challenge Model for Assessment of Human TB Immunity
Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity
Status: Enrolling
Updated:  1/25/2018
Saint Louis University - Center for Vaccine Development
mi
from
Saint Louis, MO
Challenge Model for Assessment of Human TB Immunity
Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity
Status: Enrolling
Updated: 1/25/2018
Saint Louis University - Center for Vaccine Development
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
Status: Enrolling
Updated:  1/25/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
Status: Enrolling
Updated: 1/25/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Twentynine Palms, CA
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Twentynine Palms, CA
Click here to add this to my saved trials
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated:  1/26/2018
mi
from
Fort Campbell North, KY
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated: 1/26/2018
mi
from
Fort Campbell North, KY
Click here to add this to my saved trials
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated:  1/26/2018
mi
from
Fort Bliss, TX
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated: 1/26/2018
mi
from
Fort Bliss, TX
Click here to add this to my saved trials
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated:  1/26/2018
mi
from
Fort Hood, TX
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel
Status: Enrolling
Updated: 1/26/2018
mi
from
Fort Hood, TX
Click here to add this to my saved trials
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
A Phase IV Post-licensure DOD Screening Accuracy Study in Military Personnel
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Alexandria, VA
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
A Phase IV Post-licensure DOD Screening Accuracy Study in Military Personnel
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Trial Site
mi
from
San Diego, CA
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Trial Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Trial Site
mi
from
San Francisco, CA
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Trial Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Trial Site
mi
from
Denver, CO
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Trial Site
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated:  1/26/2018
Clinical Site
mi
from
Gainesville, FL
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status: Enrolling
Updated: 1/26/2018
Clinical Site
mi
from
Gainesville, FL
Click here to add this to my saved trials